Jiangsu Kanion Pharmaceutical Co Ltd

Kangyuan Pharmaceutical released its 2026 interim report. During the reporting period, the company's total operating revenue was 1.661 billion yuan, and net profit attributable to the parent company was 147 million yuan. Net cash inflow from operating activities was 82.1004 million yuan, a decrease of 43.12% compared with the same period last year. The company's asset-liability ratio was 25.98%, gross margin was 72.91%, return on equity was 2.96%, and diluted earnings per share was 0.26 yuan. The number of shareholders was 42,600, and the top ten shareholders held 47.48% of the total share capital.

Kangyuan Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 147 million yuan, up 3.4% year on year. Operating revenue was 1.66 billion yuan, up 1.2% year on year. Net profit attributable to the parent after deducting non-recurring items was 129 million yuan, up 7.5% year on year. Net operating cash flow was 82.1 million yuan, down 43.1% year on year. Earnings per share were 0.2599 yuan. In the second quarter, operating revenue was 830 million yuan, up 8.7% year on year. Net profit attributable to the parent was 67.88 million yuan, up 15.1% year on year. Net profit attributable to the parent after deducting non-recurring items was 56.92 million yuan, up 49.8% year on year. As of the end of the second quarter, total assets were 6.972 billion yuan, up 1.6% from the end of the previous year. Net assets attributable to the parent were 4.966 billion yuan, up 3.1% from the end of the previous year. The company said that during the reporting period it continued to advance the construction of a professional marketing system, with product lines in respiratory and infectious diseases, cardiovascular and cerebrovascular diseases, and gynecology performing well. The advantages of exclusive varieties continued to be released, and the company promoted digital transformation and strengthened cooperation with pharmaceutical commercial companies, with overall operations remaining stable and improving.

Kangyuan Pharmaceutical repurchased 584,100 shares for the first time on July 16 through the Shanghai Stock Exchange via centralized bidding. This accounts for 0.1032% of the company's current total share capital. The highest purchase price was 13.75 yuan per share, and the lowest was 13.24 yuan per share. The total amount paid was approximately 7.8776 million yuan, excluding transaction fees. This buyback is part of a previously disclosed repurchase plan, which aims for a total repurchase amount of no less than 100 million yuan and no more than 200 million yuan, with a repurchase price not exceeding 20.9 yuan per share. All repurchased shares will be cancelled upon completion of the buyback.

Kanion Pharmaceutical announced that a total of 51 of its products have been included in the National Essential Medicines List, 2026 Edition, with 8 drugs newly added. In the first quarter of 2026, Kanion Pharmaceutical achieved revenue of 831 million yuan and net profit attributable to the parent company of 79.28 million yuan.